-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Wt2RmwZMmy9Hua7WYyzH6QeTLNltLIvU7SNjYCpJbZqxoVULlfz78PUNCJv0bkcw Ynq8Er/uy1HyUtSVE01YBw== 0001193125-06-022119.txt : 20060207 0001193125-06-022119.hdr.sgml : 20060207 20060207151430 ACCESSION NUMBER: 0001193125-06-022119 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060201 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20060207 DATE AS OF CHANGE: 20060207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 06585320 BUSINESS ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 5105741400 MAIL ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported):

February 1, 2006

 

 

PDL BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   000-19756   94-3023969

(State or other jurisdiction

of incorporation)

   (Commission File No.)  

(I.R.S. Employer

Identification No.)

 

34801 Campus Drive

Fremont, California 94555

(Address of principal executive offices)

 

Registrant’s telephone number, including area code:

(510) 574-1400

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 1.01 Entry Into a Material Definitive Agreement.

 

On February 1, 2006, PDL BioPharma, Inc. (the “Company”) entered into an Amended and Restated Consulting Agreement effective as of January 2, 2006 (the “Agreement”) with Cary L. Queen, Ph.D., a member of the Board of Directors of the Company. The Agreement is a continuation of the Company’s original Consulting Agreement with Dr. Queen dated as of January 2, 2004. Pursuant to the Agreement, Dr. Queen will continue to advise the Company on patent matters and on the Queen, et. al. family of humanization patents in particular. For his services, Dr. Queen will receive $100,000 per annum, paid quarterly, and the continued vesting of certain previous Company stock option grants.

 

2

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 7, 2006

 

PDL BIOPHARMA, INC.
By:  

/s/ Mark McDade

    Mark McDade
    Chief Executive Officer

 

3

-----END PRIVACY-ENHANCED MESSAGE-----